AnaCardio reports first patient dosed in the GOAL-HF1 study, a Phase 1b/2a Clinical Study in Heart Failure with AC01 in the EU and UK
Solna, Sweden and Lugano, Switzerland, April 13, 2022 - AnaCardio, a Swedish clinical-stage biopharmaceutical company focussed on developing novel contractile agents with a unique mode-of-action based on the ghrelin signaling pathway, today announced that the first patient has been successfully dosed in its GOAL-HF1 study of AC01 in patients with heart failure and reduced ejection fraction (HFrEF). AnaCardio licensed AC01, an oral ghrelin peptidomimetic small-molecule, from Helsinn Group in February 2022. As previously announced, the GOAL-HF1 study is a Phase 1b/2a multicenter,